Search results :


More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: C02KX02

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6
Oedema peripheral 17.2% - 28.4% 10.6% x x x x x x
Headache very common, 14.6% - 19.4% 13.6% x x x x x
Sinus headache very common x x x
Migraine very common x x x
Dizziness postmarketing, 6.92% - 8.96% 9.85% x x x x x
Cough 5.38% - 7.46% 6.06% x x x
Upper respiratory tract infection 4.62% - 7.46% 6.06% x x x
Nasal congestion common, 5.38% - 10.4% 1.52% x x x x x x
Dyspnoea exacerbated 1.49% - 7.69% 6.06% x x x
Dyspnoea postmarketing, 4.21% - 5.38% 3.03% x x x x x
Fatigue postmarketing, 4.48% - 5.38% 4.55% x x x x
Palpitations common, 3.85% - 4.6% 2.27% x x x x x
Nausea postmarketing, 3.85% - 4.48% 9.09% x x x x x
Constipation common, 3.08% - 5.97% 1.52% x x x x x
Flushing common, 1.49% - 3.85% 0.758% x x x x x x
Epistaxis 1.54% - 5.97% 3.79% x x x
Nasopharyngitis common, 2.99% - 5.38% 0.758% x x x x x
Sinusitis common, 3.07% - 4.48% 0% x x x x x x
Abdominal pain common, 2.99% - 3.08% 0.758% x x x x x
Bronchitis 1.49% - 4.62% 3.79% x x
Chest pain 1.49% - 4.62% 2.27% x x x x
Right ventricular failure 1.49% - 4.62% 12.1% x x x
Aspartate aminotransferase increased 1.54% - 2.99% 3.79% x x
Insomnia 1.49% - 2.31% 3.03% x x x
Arthralgia 0.769% - 2.99% 3.79% x x x
Urinary tract infection 1.49% - 1.54% 6.06% x x
Pulmonary hypertension 0.769% - 1.49% 5.3% x x x x
Rash postmarketing, uncommon x x x x x
Hypersensitivity postmarketing, uncommon x x x x x
Anaemia postmarketing x x x x x
Angioedema postmarketing x x x
Asthenia postmarketing x x x x
Gastrointestinal disorder postmarketing x x x x
Cardiac disorder postmarketing x x x x
Cardiac failure postmarketing x x x x
Hepatitis postmarketing x
Mediastinal disorder postmarketing x x x x
Nervous system disorder postmarketing x x x
Vomiting postmarketing x x x x
Hepatic failure postmarketing x
Liver injury postmarketing x x x x
Hepatotoxicity postmarketing x
Autoimmune hepatitis postmarketing x x x
Hepatobiliary disease postmarketing x x x
Hepatic congestion postmarketing x
Fluid retention postmarketing x x x x x x
Transaminases increased postmarketing x x x
Blood and lymphatic system disorders postmarketing x x x
Angina pectoris x
Anorexia x
Mental disorder x
Breast disorder x
Infection x
Contusion x
Diarrhoea x x
Oedema x
Body temperature increased x
Gastritis x
Blood disorder x
Haemorrhage x
Hypokalaemia x
Hypotension x
Immune system disorder x x x x
Influenza x
Cramp muscle x
Nocturia x
Pharyngitis x
Pleural effusion x
Pneumonia x
Pruritus x x
Pulmonary oedema x
Pulmonary veno-occlusive disease x
Rales x
Rhinitis x x
Skin ulcer x
Syncope x
Tachycardia x
Urinary tract disorder x
Angiopathy x x x
Wheezing x
Haemoglobin decreased x x x x
Malnutrition x
Myalgia x
Abdominal pain upper x
Discomfort x
Chest discomfort x
Non-cardiac chest pain x
Haematocrit decreased x x
Infestation NOS x
Sleep disorder x
Sperm count decreased x
Vaginal haemorrhage x


Information about indications was extracted from the indications and usage sections of the labels.


Side effects:12


Side effects:23
Source:FDA Structured Product Label

ambrisentan / ambrisentan

Side effects:44

ambrisentan / VOLIBRIS

Side effects:46

VOLIBRIS / Volibris, Tablet

Side effects:46


Side effects:65
Source:Health Canada

Color scheme:


    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    no frequency information
    not found on label